Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

3.965 -0.025 (-0.63%)
Streaming Delayed Price Updated: 3:17 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,725,604
Open 3.990
Bid (Size) 3.960 (3,300)
Ask (Size) 3.970 (1,300)
Prev. Close 3.990
Today's Range 3.830 - 4.140
52wk Range 2.530 - 5.450
Shares Outstanding 65,837,894
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+14.6%
+14.6%
1 Month
+46.9%
+46.9%
3 Month
+14.6%
+14.6%
6 Month
+11.7%
+11.7%
1 Year
+41.1%
+41.1%

More News

Read More
News headline image
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Posts Narrower Q3 2025 Loss, Advances Gene Therapy Pipeline ↗
Via Chartmill
News headline image
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy ↗
Via Benzinga
News headline image
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock ↗
Via Benzinga
News headline image
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy ↗
Via Stocktwits
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
Via Benzinga
News headline image
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
From Rocket Pharmaceuticals, Inc.
Via Business Wire
News headline image
Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga

Frequently Asked Questions

Is Rocket Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Rocket Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Rocket Pharmaceuticals, Inc. - Common Stock trade on?
Rocket Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Rocket Pharmaceuticals, Inc. - Common Stock is RCKT on the Nasdaq Stock Market
What is the current price of Rocket Pharmaceuticals, Inc. - Common Stock?
The current price of Rocket Pharmaceuticals, Inc. - Common Stock is 3.965
When was Rocket Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Rocket Pharmaceuticals, Inc. - Common Stock was at 07/07/26 03:17 PM ET
What is the market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Rocket Pharmaceuticals, Inc. - Common Stock is 261.05M
How many shares of Rocket Pharmaceuticals, Inc. - Common Stock are outstanding?
Rocket Pharmaceuticals, Inc. - Common Stock has 261M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.